Apotex has announced it has received the first US Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application (ANDA) for Semaglutide Injection, marking a significant milestone in expanding affordable access to complex peptide therapies for patients across the United States.
This approval reinforces Apotex’s leadership in bringing high value, technically challenging medicines that help improve patient access and support a more sustainable healthcare system. It’s further proof of the company’s longstanding commitment to scientific excellence and advancing complex generics that can help reduce costs for patients and payers.
Developed through a strategic partnership with Orbicular Pharmaceutical Technologies, the Semaglutide Injection program is a result of sophisticated development capabilities, including advanced analytical characterization and deep process understanding.
‘This is a clear demonstration of what true partnership can achieve,’ said Barry Fishman, Chief Corporate Development Officer, Apotex. ‘As a Force for Health, this milestone reflects Apotex’s leadership in bringing together complementary strengths, a shared purpose, and an unwavering commitment to execution excellence.’
The FDA Tentative Approval underscores the strength of Apotex’s global development model and its ability to deliver complex generics that meet rigorous regulatory requirements. Upon becoming eligible for final approval, Apotex’s Semaglutide Injection is expected to help broaden patient access to an important therapy area where affordability and availability remain critical.
